Literature DB >> 1572482

Embryo transfer to the uterus or the fallopian tube after in vitro fertilization yields similar results.

T L Toth1, S Oehninger, J P Toner, R G Brzyski, A A Acosta, S J Muasher.   

Abstract

The outcome of ZIFT and IVF-ET was compared in consecutive nontubal factor patients in a prospective fashion. Groups did not differ in characteristics and were matched by the number of prezygotes/pre-embryos transferred. Overall, implantation, pregnancy, miscarriage, and ongoing PRs were not statistically different. These results suggest that ZIFT offers no significant advantage over IVF-ET for the treatment of nontubal infertility.

Entities:  

Mesh:

Year:  1992        PMID: 1572482     DOI: 10.1016/s0015-0282(16)55033-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  IVF, GIFT, or ZIFT.

Authors:  D Meldrum
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

2.  The role of gamete intrafallopian transfer (GIFT) and tubal embryo transfer (TET) in the treatment of patients with patent tubes associated with male infertility factor.

Authors:  R Seracchioli; A Maccolini; E Porcu; A Borini; M Cattoli; P Ciotti; F Violini; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1993-05       Impact factor: 3.412

3.  Methodology of human embryo transfer following assisted reproduction.

Authors:  S Friedler; A Lewin; J G Schenker
Journal:  J Assist Reprod Genet       Date:  1993-08       Impact factor: 3.412

4.  Conversion from a failed transcervical zygote intrafallopian transfer to a successful delayed uterine embryo transfer.

Authors:  B S Hurst; K A Faber; S Guadagnoli; W H Persutte; C A Awoniy; K F Tucker; W D Schlaff
Journal:  J Assist Reprod Genet       Date:  1993-08       Impact factor: 3.412

5.  In vitro fertilization (IVF): a review of 3 decades of clinical innovation and technological advancement.

Authors:  Jeff Wang; Mark V Sauer
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.